Predictive Oncology Inc. announced the appointment of Mr. Andrew Einhorn to its Business Advisory Board. Mr. Andrew Einhorn works for Danforth Advisors, builders of life science companies with deep institutional knowledge of the business of life sciences from strategy through execution, where he provides financial advisory services to public and privately held companies. He was appointed interim chief financial officer of Cognition Therapeutics in August 2022.

Previously, Mr. Einhorn served as chief financial officer of RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc), Edge Therapeutics Inc., and was co-founder and CFO of Oceana Therapeutics Inc., Esprit Pharma Inc. and ESP Pharma Inc. Earlier in his career, Mr. Einhorn was in investment banking and capital markets at PNC Bank, Chase Securities, and BT Securities, where he managed debt, equity and structured financing transactions with institutional investors. Mr. Einhorn is a former certified public accountant licensed by the American Institute of Certified Public Accountants and the New Jersey Society of CPAs. He is a graduate of The American University with a degree in finance and accounting.